Gene Therapies: Reimbursement Challenges and Pricing Opportunities in the US
Author(s)
Moderator: Omar Dabbous, MD, MPH, Global HEOR and RWE, Novartis Gene Therapies, Bannockburn, IL, USA
Speakers: Michael Drummond, MCom, DPhil, Centre for Health Economics, University of York, York, YOR, UK; Peter Neumann, ScD, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Lou Garrison, PhD, University of Washington, Seattle, WA, USA
Economic evaluation studies may underestimate the value of innovative cell and gene therapies in rare diseases, impacting on Health Technology Assessment (HTA) frameworks, market access and pricing decisions. This symposium will explore the challenges faced by HTA and other reimbursement bodies, as they consider a wide range of cell and gene therapies. Panelists will discuss drug value evidence-based challenges, the coverage policies that global payers have used to address these challenges, and their impact on value assessment frameworks, contracting and affordability.
Conference/Value in Health Info
2021-05, ISPOR 2021, Montreal, Canada